These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
698 related articles for article (PubMed ID: 23642377)
1. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Jaffe GJ; Martin DF; Toth CA; Daniel E; Maguire MG; Ying GS; Grunwald JE; Huang J; Ophthalmology; 2013 Sep; 120(9):1860-70. PubMed ID: 23642377 [TBL] [Abstract][Full Text] [Related]
2. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials. Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ; Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095 [TBL] [Abstract][Full Text] [Related]
3. Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials. Jaffe GJ; Ying GS; Toth CA; Daniel E; Grunwald JE; Martin DF; Maguire MG; Ophthalmology; 2019 Feb; 126(2):252-260. PubMed ID: 30189282 [TBL] [Abstract][Full Text] [Related]
4. Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. ; Maguire MG; Martin DF; Ying GS; Jaffe GJ; Daniel E; Grunwald JE; Toth CA; Ferris FL; Fine SL Ophthalmology; 2016 Aug; 123(8):1751-1761. PubMed ID: 27156698 [TBL] [Abstract][Full Text] [Related]
5. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ying GS; Huang J; Maguire MG; Jaffe GJ; Grunwald JE; Toth C; Daniel E; Klein M; Pieramici D; Wells J; Martin DF; Ophthalmology; 2013 Jan; 120(1):122-9. PubMed ID: 23047002 [TBL] [Abstract][Full Text] [Related]
6. Five-Year Follow-up of Nonfibrotic Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Daniel E; Ying GS; Kim BJ; Toth CA; Ferris F; Martin DF; Grunwald JE; Jaffe GJ; Dunaief JL; Pan W; Maguire MG; Ophthalmology; 2019 May; 126(5):743-751. PubMed ID: 30476517 [TBL] [Abstract][Full Text] [Related]
7. Risk of scar in the comparison of age-related macular degeneration treatments trials. Daniel E; Toth CA; Grunwald JE; Jaffe GJ; Martin DF; Fine SL; Huang J; Ying GS; Hagstrom SA; Winter K; Maguire MG; Ophthalmology; 2014 Mar; 121(3):656-66. PubMed ID: 24314839 [TBL] [Abstract][Full Text] [Related]
8. Predominantly Persistent Subretinal Fluid in the Comparison of Age-Related Macular Degeneration Treatments Trials. Core JQ; Pistilli M; Daniel E; Grunwald JE; Toth CA; Jaffe GJ; Hua P; Martin DF; Ying GS; Maguire MG; Ophthalmol Retina; 2021 Oct; 5(10):962-974. PubMed ID: 34126249 [TBL] [Abstract][Full Text] [Related]
9. Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Shah N; Maguire MG; Martin DF; Shaffer J; Ying GS; Grunwald JE; Toth CA; Jaffe GJ; Daniel E; Ophthalmology; 2016 Apr; 123(4):858-64. PubMed ID: 26778329 [TBL] [Abstract][Full Text] [Related]
10. Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials. Willoughby AS; Ying GS; Toth CA; Maguire MG; Burns RE; Grunwald JE; Daniel E; Jaffe GJ; Ophthalmology; 2015 Sep; 122(9):1846-53.e5. PubMed ID: 26143666 [TBL] [Abstract][Full Text] [Related]
11. Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ciulla TA; Ying GS; Maguire MG; Martin DF; Jaffe GJ; Grunwald JE; Daniel E; Toth CA; Ophthalmology; 2015 Jun; 122(6):1203-11. PubMed ID: 25824327 [TBL] [Abstract][Full Text] [Related]
12. Predominantly Persistent Intraretinal Fluid in the Comparison of Age-related Macular Degeneration Treatments Trials. Core JQ; Pistilli M; Hua P; Daniel E; Grunwald JE; Toth CA; Jaffe GJ; Martin DF; Maguire MG; Ying GS; Ophthalmol Retina; 2022 Sep; 6(9):771-785. PubMed ID: 35405352 [TBL] [Abstract][Full Text] [Related]
13. Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). Altaweel MM; Daniel E; Martin DF; Mittra RA; Grunwald JE; Lai MM; Melamud A; Morse LS; Huang J; Ferris FL; Fine SL; Maguire MG; ; Ophthalmology; 2015 Feb; 122(2):391-398.e5. PubMed ID: 25307130 [TBL] [Abstract][Full Text] [Related]